1. Home
  2. OPTN

OPTN

OptiNose Inc.

Logo OptiNose Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

Founded: 2010 Country:
United States
United States
Employees: N/A City: YARDLEY
Market Cap: 137.4M IPO Year: 2017
Target Price: $4.00 AVG Volume (30 days): 574.5K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.32 EPS Growth: N/A
52 Week Low/High: $0.90 - $2.10 Next Earning Date: 05-09-2024
Revenue: $70,987,000 Revenue Growth: -6.93%
Revenue Growth (this year): 31.3% Revenue Growth (next year): 42.18%

Share on Social Networks: